location: Current position: Home >> Scientific Research >> Paper Publications

Kruppel-like factor 9 down-regulates matrix metalloproteinase 9 transcription and suppresses human breast cancer invasion

Hits:

Indexed by:期刊论文

Date of Publication:2018-01-01

Journal:CANCER LETTERS

Included Journals:SCIE、PubMed

Volume:412

Issue:412

Page Number:224-235

ISSN No.:0304-3835

Key Words:Kruppel-like factor 9; Matrix metalloproteinase 9; Human breast cancer; Invasion; Metastasis

Abstract:Kruppel-like factor 9 (KLF9) plays critical roles in several types of tumor. However, the biological functions and the underlying mechanisms of KLF9 in breast cancer metastasis are still unknown. Here, we found the expression of KLF9 was significantly down-regulated in breast cancer and was inversely correlated with the expression of matrix metalloproteinase 9 (MMP9) in breast cancer patients. Functionally, KLF9 transcriptionally down-regulated MMP9 expression and inhibited the metastasis of breast cancer cells. Mechanistically, KLF9 repressed human MMP9 promoter activity by binding to the CACCC motif and interacting with NF-kappa B p50/p65, which interacted with the NF-kappa B response element of the MMP9 promoter, leading to decreased expression of MMP9. In the context of breast cancer, KLF9 promoted the accumulation of HDAC1, thereby decreasing the acetylation of the KLF9-binding site on the MMP9 promoter, and this might be the molecular basis of KLF9-mediated inhibition of MMP9 transcription. In addition to MMP9, KLF9 also down-regulated several other NF-kappa B targets, such as TNF-alpha, VEGFA and uPA in breast cancer cells. Taken together, these results uncovered a new mechanism by which KLF9 could down-regulate MMP9 expression to inhibit breast cancer metastasis. (C) 2017 Elsevier B.V. All rights reserved.

Pre One:α-catenin SUMOylation increases IκBαstability and inhibits breast cancer progression

Next One:Checkpoint suppressor 1 suppresses transcriptional activity of ERalpha and breast cancer cell proliferation via deacetylase SIRT1.